Reply: Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir

Abstract

Get full access to this article

View all access options for this article.

References

Yoong

Naccarato

Gough

. Extensive bruising and elevated rivaroxaban plasma concentration in a patient receiving cobicistat-boosted elvitegravir [published online March 1, 2017]. Ann Pharmacother. doi:10.1177/1060028017702677

Kelley

Sebaaly

. Comment: extensive bruising and elevated rivaroxaban plasma concentration in a patient receiving cobicistat-boosted elvitegravir. Ann Pharmacother. 2007;51:929-930.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL003400.pdf

US Food and Drug Administration. Drugs@FDA: FDA approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed May 20, 2017.

Sheehan

Kelly

Tseng

van Heeswijk

Beique

Hughes

; Canadian HIV/AIDS Pharmacists Network. Evaluation of HIV drug interaction web sites. Ann Pharmacother. 2003;37:1577-1586.

Tannenbaum

Sheehan

NL.

Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7:533-544. doi:10.1586/17512433.2014.910111